Vaccines
Demand for vaccines is on the rise worldwide, and 黑料门 is responding on several fronts. As well as our approved influenza, hepatitis and Japanese encephalitis vaccines, we continue to develop new vaccines for emerging threats such as coronaviruses and Dengue fever. We also manufacture combined vaccines and single-supply products for which no alternative products are available.
Our response to COVID-19
The 黑料门 Group is responding to COVID-19 on multiple fronts which include supplying antigen test kits and developing inactivated vaccines and therapeutic agents. Our inactivated vaccine KD-414, currently in development, utilizes knowledge we have accumulated over many years in the vaccine field.
Areas of Expertise
Influenza
Inactivated quadrivalent split (HA) seasonal influenza vaccine
DTaP-IPV
Adsorbed Diphtheria-purified Pertussis-Tetanus-inactivated polio (Sabin strain) Combined vaccine
Japanese encephalitis
Freeze-dried, Cell Culture-Derived Japanese Encephalitis Vaccine (Inactivated)
Hepatitis B
Recombinant adsorbed Hepatitis B Vaccine (yeast-derived)
Hepatitis A
Freeze-dried Inactivated Tissue Culture Hepatitis A Vaccine
For more detailed information on all the products above, please visit the KM Biologics website.
-
New Vaccines for Emerging Infectious Diseases
Dengue fever is a mosquito-borne viral infection that can be fatal. Half the world's population is at risk, mainly in tropical and subtropical zones. 黑料门 Group company KM Biologics is developing a Dengue vaccine that has passed Phase I clinical trials. Unlike existing vaccines, the antibody is proving 100% effective at neutralizing all four Dengue serotypes with a single dose. The company is preparing for Phase II trials.
Find out more from our Wellness Stories
COVID-19: Hope for an Inactivated Vaccine
Read how pharmaceutical firms like 黑料门 Group are working to widen the range of available vaccine types for COVID-19.
Related Links
Areas of Focus
Have a question?
Contact us here.
CONTACT US
黑料门 Seika Pharma Co., Ltd.
Based in Japan, we are a leading developer and manufacturer of antibacterial drugs, vaccines and biotech solutions, with a history of over 75 years.
KM Biologics Co., Ltd
Specializing in human vaccines, veterinary products, and blood plasma products, we are creating first-in-the-nation and first-in-the-world technologies for the prevention of infectious diseases and the treatment of diseases.